Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8059 ARTÍCULOS , VIENDO DEL 4171 AL 4185

Sembragiline in Moderate Alzheimer's Disease: Results of a Randomized, Double-Blind, Placebo-Controlled Phase II Trial (MAyflOwer RoAD)

Nave S, Doody RS, Boada M, Grimmer T, Savola JM, Delmar P, Pauly-Evers M, Nikolcheva T, Czech C, Borroni E, Ricci B, Dukart J, Mannino M, Carey T, Moran E, Gilaberte I, Muelhardt NM, Gerlach I, Santarelli L, Ostrowitzki S, Fontoura P.

J Alzheimers Dis. 2017;58(4):1217-1228. doi: 10.3233/JAD-161309.

Adverse Events With Sustained-Release Donepezil in Alzheimer Disease: Relation to Body Mass Index

Lee C, Lee K, Yu H, Ryu SH, Moon SW, Han C, Lee JY, Lee YM, Kim SG, Kim KW, Lee DW, Kim SY, Lee SY, Bae JN, Jung YE, Kim JL, Kim BS, Shin IS, Kim YH, Kim BJ, Kang HS, Myung W, Carroll BJ, Kim DK.

J Clin Psychopharmacol. 2017 Aug;37(4):401-404. doi: 10.1097/JCP.0000000000000726.

Acute cholinergic syndrome in a patient with mild Alzheimer's type dementia who had applied a large number of rivastigmine transdermal patches on her body

Suzuki Y, Kamijo Y, Yoshizawa T, Fujita Y, Usui K, Kishino T.

Clin Toxicol (Phila). 2017 Nov;55(9):1008-1010. doi: 10.1080/15563650.2017.1329536. Epub 2017 Jun 8.

Advances in Alzheimer's Diagnosis and Therapy: The Implications of Nanotechnology

Hajipour MJ, Santoso MR, Rezaee F, Aghaverdi H, Mahmoudi M, Perry G.

Trends Biotechnol. 2017 Oct;35(10):937-953. doi: 10.1016/j.tibtech.2017.06.002. Epub 2017 Jun 27.

Cholinergic symptoms and QTc prolongation following donepezil overdose

Pourmand A, Shay C, Redha W, Aalam A, Mazer-Amirshahi M.

Am J Emerg Med. 2017 Sep;35(9):1386.e1-1386.e3. doi: 10.1016/j.ajem.2017.06.044. Epub 2017 Jun 22.

Winning the Fight to End Alzheimer Disease

Dawson W.

JAMA Neurol. 2017 Aug 1;74(8):896-897. doi: 10.1001/jamaneurol.2017.1279.

Alzheimer's Disease: Dawn of a New Era?

Amirrad F, Bousoik E, Shamloo K, Al-Shiyab H, Nguyen VV, Montazeri Aliabadi H.

J Pharm Pharm Sci. 2017;20(0):184-225. doi: 10.18433/J3VS8P.

I-SPY 2 Breast Cancer Trial as a Model for Innovation in Alzheimer Disease Therapies

Messmer MF, Wilhelm EE, Shoulson I.

JAMA Neurol. 2017 Sep 1;74(9):1027-1028. doi: 10.1001/jamaneurol.2017.1528.

Cognitive behavioral therapy (CBT) for preventing Alzheimer's disease

Reid LD, Avens FE, Walf AA.

Behav Brain Res. 2017 Sep 15;334:163-177. doi: 10.1016/j.bbr.2017.07.024. Epub 2017 Jul 23.

The medical food Souvenaid affects brain phospholipid metabolism in mild Alzheimer's disease: results from a randomized controlled trial

Rijpma A, van der Graaf M, Lansbergen MM, Meulenbroek O, Cetinyurek-Yavuz A, Sijben JW, Heerschap A, Olde Rikkert MGM.

Alzheimers Res Ther. 2017 Jul 26;9(1):51. doi: 10.1186/s13195-017-0286-2.

Baseline Telomere Length and Effects of a Multidomain Lifestyle Intervention on Cognition: The FINGER Randomized Controlled Trial

Sindi S, Ngandu T, Hovatta I, Kåreholt I, Antikainen R, Hänninen T, Levälahti E, Laatikainen T, Lindström J, Paajanen T, Peltonen M, Khalsa DS, Wolozin B, Strandberg T, Tuomilehto J, Soininen H, Kivipelto M, Solomon A; FINGER study group.

J Alzheimers Dis. 2017;59(4):1459-1470. doi: 10.3233/JAD-170123.

Efficacy and tolerability of rivastigmine patch therapy in patients with mild-to-moderate Alzheimer's dementia associated with minimal and moderate ischemic white matter hyperintensities: A multicenter prospective open-label clinical trial

Park KW, Kim EJ, Han HJ, Shim YS, Kwon JC, Ku BD, Park KH, Yi HA, Kim KK, Yang DW, Lee HW, Kang H, Kwon OD, Kim S, Lee JH, Chung EJ, Park SW, Park MY, Yoon B, Kim BC, Seo SW, Choi SH.

PLoS One. 2017 Aug 7;12(8):e0182123. doi: 10.1371/journal.pone.0182123. eCollection 2017.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias